-
Will Actavis Win Competition For Allergan's Affection?
Thursday, October 16, 2014 - 11:10am | 839Read More...Four pharmaceutical companies have been flirting with merger deals. Discussing the confusing courting, Barron’s called them the Bob & Carol & Ted & Alice of pharmaceuticals, referencing the sexy 1969 comedy-drama with the tag line “Consider the Possibilities.” In...
-
#PreMarket Primer: Wednesday, October 8: IMF Cuts Global Growth Prospects, Puts A Damper On Wall Street
Wednesday, October 8, 2014 - 8:19am | 1300Read More...On Tuesday, the International Monetary Fund reduced its global economic growth forecast for the current year for the ninth time in the past three years. The fund reduced this year’s growth expectation to 3.3 percent and also trimmed its 2015 forecast to 3.4 percent, citing slackening...
-
UPDATE: Credit Suisse Downgrades Allergan
Tuesday, June 3, 2014 - 11:00am | 133Read More...Allergan (NYSE: AGN) on Tuesday was downgraded to Neutral from Outperform by Credit Suisse due to a balanced risk/reward profile following the latest takeover offer from Valeant Pharmaceuticals International. Stating that the latest Valeant Pharmaceuticals offer warrants consideration, Credit...
-
Valeant Pharmaceuticals to Buy Bausch & Lomb
Tuesday, May 28, 2013 - 12:20pm | 570Read More...It’s a sign of the times in health care. If you can’t generate growth, buy it. The New York Times sounded that familiar theme in reporting the pending acquisition Monday of Rochester, N ew York-based Bausch & Lomb by Canadian drugmaker Valeant Pharmaceuticals (NYSE: VRX). J. Michael...
-
Warner Chilcott, Valeant Pharmaceuticals Share Several Attractive Attributes, Bank of America Reports
Wednesday, June 15, 2011 - 7:44am | 150Read More...In addition to being large Specialty Pharma companies, Bank of America reports that “Warner Chilcott plc (NASDAQ: WCRX) and Valeant Pharmaceuticals International, Inc. (NYSE: VRX) share several attractive attributes, including high margins, strong cash flow generation, and favorable tax structures...
-
UPDATE: Goldman Sachs Reinstates Valeant Pharmaceuticals International at Neutral (VRX)
Tuesday, May 10, 2011 - 8:07am | 77Read More...Goldman Sachs is out with its report today on Valeant Pharmaceuticals International (NYSE: VRX), reinstating VRX at Neutral. In a note to clients, Goldman Sachs writes, "In conjunction with 1Q results and the recent withdrawal of its consent solicitation to acquire Cephalon, we remove our Not...
-
Piper Jaffray Reiterates OW Rating On VRX
Wednesday, March 30, 2011 - 8:24am | 175Read More...Piper Jaffray is reiterating its OW rating on shares of Valeant Pharmaceuticals International, Inc. (NYSE: VRX). “Last night, Valeant announced that it is making an unsolicited offer to acquire Cephalon Inc. (NASDAQ: CEPH) for $73 per share in an all-cash transaction,” Piper Jaffray writes. “Even...
-
Goldman Sachs Moves VRX To Not Rated
Wednesday, March 30, 2011 - 7:38am | 109Read More...Goldman Sachs reports that the Americas Investment Review Committee has determined that the rating and price target for Valeant Pharmaceuticals International, Inc. (NYSE: VRX) should be removed. “Goldman Sachs is acting as a financial advisor in connection with a matter that is fundamental to the...
